Articles from AcuityMD

AcuityMD, the AI platform for MedTech, today announced the availability of health network intelligence in AcuityAI, giving MedTech commercial teams a comprehensive view of healthcare sites, sales performance, and opportunities across health systems and purchasing networks. Sales teams can ask AcuityAI about integrated delivery networks (IDNs), group purchasing organizations (GPOs), regional purchasing coalitions (RPCs), and management services organizations (MSOs) and get instant responses grounded in AcuityMD’s trusted network data.

AcuityMD, the AI platform for MedTech, today announced AcuityAI Artifacts, a new capability that transforms AI-generated insights into structured, reusable content for commercial teams. With Artifacts, users can turn AcuityAI conversations into call plans, market analyses, account comparisons, targeting lists, and reports that can be easily saved, refined, and exported. Artifacts ensure valuable insights extend beyond a single conversation, enabling teams to continuously build on and benefit from that intelligence.

AcuityMD, the AI platform for MedTech, today introduced advanced market analysis in AcuityAI, powered by a new research agent that delivers company, brand, and product-level market share, pricing comparisons, and patient pathway analyses to calculate total addressable market size in minutes. MedTech leaders gain fast, accurate market analysis – a traditionally time-consuming process – to improve long-term decision-making.

AcuityMD, the AI platform for MedTech, today announced the availability of prescription data in AcuityAI, combining prescription and procedure data in a single workflow for commercial teams. Sales reps can use AcuityAI to find and prioritize healthcare professionals (HCPs) treating patients with prescription (branded and generic) therapies that align with their targets.

AcuityMD, the AI platform for MedTech, today announced it has been named to the 2026 Inc. 5000 list of the fastest-growing private companies in America. AcuityMD ranked No. 316, driven by 1,061% three-year revenue growth – roughly 10 times the median revenue growth rate of 130% among 2026 Inc. 5000 honorees. The company also ranked No. 28 out of 362 software companies on the list. This marks AcuityMD’s first appearance on Inc. Magazine’s prestigious annual ranking.

AcuityMD, the AI platform for MedTech, today announced it is now trusted by more than 500 medical device (MedTech) companies, including 16 of the top 20, such as Becton Dickinson, Olympus, and Teleflex. The milestone reflects a growing shift across the medical device industry, as commercial teams adopt AI to better understand where care is happening and to uncover new opportunities. Across its customer base, AcuityMD has helped commercial teams generate billions in pipeline opportunities in the past year alone. Now, with AcuityAI, the company expects even faster growth and adoption of AI.

AcuityMD, the AI platform for MedTech, today announced findings from its new AI survey, revealing a strong link between AI adoption and sales performance. The new report, AI Adoption in MedTech Sales: 2026 Industry Benchmarks and Trends, finds that medical device sales reps who use AI at work are three times more likely to meet or exceed quota than those who do not use AI. Conversely, reps who did not meet quota were almost twice as likely to have never used AI professionally.

AcuityMD today announced that it has launched the AcuityMD Encounters Data Mart on Snowflake Marketplace. The AcuityMD Encounters Data Mart provides MedTech organizations with insights into procedure volumes, provider activity, and healthcare delivery locations across the United States, enabling joint customers to quantify market opportunity and identify high-value providers and sites of care.

AcuityMD, the AI platform for MedTech, today announced $80 million in new funding to elevate its platform with advanced artificial intelligence (AI) capabilities and drive the company’s mission of accelerating adoption of medical technology. The Series C round was led by existing investor StepStone Group, with additional participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. Now supporting 16 of the top 20 MedTech companies and having helped customers identify over $34 billion in pipeline, AcuityMD has raised more than $160 million to date and is valued at $955 million.

AcuityMD, the intelligence platform for MedTech, announced data revealing increased access to colorectal screening and early treatment at ambulatory surgery centers (ASCs). Across the U.S., the majority of all endoscopic colorectal procedures are now performed in ASCs, lowering barriers to care for patients who might delay or avoid screening. ASCs handled nearly 9 million endoscopic colorectal procedures in 2024 alone, a 50% volume increase since 2018.

AcuityMD today announced it has launched AcuityMD for Salesforce on Salesforce AppExchange, the leading enterprise marketplace for partner apps and experts, empowering customers to integrate AcuityMD’s platform directly with Salesforce to help commercial teams identify opportunities, research and prioritize targets, and hit sales goals faster.

In recognition of Veterans Day, AcuityMD announces its partnership with Electromedical Products International (EPI) to drive access to Alpha-Stim®, a non-invasive, FDA-cleared device that uses cranial electrotherapy stimulation (CES) and microcurrent electrical therapy (MET) to treat anxiety, insomnia, and pain for U.S. military veterans. While available to all patients diagnosed with these conditions, Alpha-Stim is uniquely appealing to veterans who may have concerns with long-term prescription drug treatments. Through its partnership with AcuityMD, EPI has expanded its use to community care providers and has achieved major gains in both pipeline growth and technology adoption.

In recognition of Children’s Health Month, AcuityMD, the AI platform for MedTech, announced that Preceptis Medical has selected its platform to support an expanded market launch of the Hummingbird® Tympanostomy Tube System (TTS). TTS offers a unique approach for pediatric ear tube placement in the office without the need for the operating room or general anesthesia. Preceptis Medical, a medical device company focused on office-based options for pediatric patients, chose AcuityMD for its deep industry expertise, comprehensive market data, and AI-driven insights to guide commercial decision making.

AcuityMD, the AI platform for MedTech, announced today at its annual Flywheel event for commercial leaders a major expansion of its platform with new AI tools to give medical device companies visibility into forecasted sales performance, business risks, and next-best actions to reach their goals. AcuityMD is modernizing how MedTech companies go to market by applying AI to improve efficiency and effectiveness – ultimately accelerating the delivery of life-changing medical innovations to patients.

AcuityMD, the MedTech Intelligence Platform, has been named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation. The list has a strong track record: more than 100 startups named in the past 10 years have since become unicorns.

AcuityMD, the MedTech Intelligence Platform, today announced a new solution that will help MedTech companies and healthcare providers (HCPs) deliver new treatment options to more patients. Referral Pathways in AcuityMD Care Journeys provides comprehensive patient referral data so MedTech commercial teams can easily identify the physicians who can most benefit from their products and bring innovations to more patients.

AcuityMD, the intelligence platform for MedTech, announced impressive growth and milestone achievements in 2024. Over the past year, AcuityMD contracted with its 300th customer, launched two innovative products, and doubled its staff. Further, after a $45 million Series B funding in June 2024, AcuityMD has now raised more than $83 million. With the global medical devices market size projected to grow from $542.21 billion in 2024 to $886.80 billion by 2032, AcuityMD is positioned for continued growth ahead.

AcuityMD, the intelligence platform for MedTech, is presenting new data on increased outpatient spinal surgeries at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting. The share of spinal surgeries performed in ambulatory surgery centers (ASCs) has steadily increased nearly 8% year-over-year from 2021 through 2024. The many benefits for patients, payers, and providers are driving current trends. For instance, ASCs can be 45-60% less expensive than hospitals and the Department of Health and Human Services estimated savings of $15 billion to taxpayers and $3 billion to Medicare patients if all qualifying surgeries were performed at ASCs.

AcuityMD, the intelligence platform for the medical technology (MedTech) industry, has been selected by Profound Medical, a medical device company developing customizable, incision-free therapies that combine real-time magnetic resonance imaging, thermal ultrasound, and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue – specifically for prostate diseases. Profound Medical is standardizing its organization on AcuityMD’s complete suite of commercial intelligence solutions to bring its breakthrough TULSA-PRO® technology to more healthcare providers nationwide.

AcuityMD, a leading technology provider to the medical technology (MedTech) industry, today announced the launch of AcuityMD Care Journeys to help MedTech companies efficiently bring their innovations to the right patients by harnessing longitudinal, patient-level data for more precise targeting. Care Journeys also empowers commercial teams to demonstrate the value of their products to physicians, hospitals, and independent delivery networks (IDNs), driving revenue and improving patient care.

AcuityMD, a leading technology provider to the commercial medical technology (MedTech) industry, today announced AcuityMD Contracts, the first contract management solution built to help MedTech companies maximize contract revenue and market penetration. AcuityMD Contracts solves the longstanding challenge of managing multifaceted contracts in an increasingly complex healthcare environment.

AcuityMD, a leading technology provider to the commercial medical technology (MedTech) industry, today announced results of a new survey quantifying the value of contracts and the severity of poor contract management in MedTech. Two-thirds of respondents report that at least 70% of company revenue is earned through contracts and that percentage is anticipated to grow to 80% by 2027. All respondents say their companies could unlock additional revenue if they could fully leverage negotiated contracts.

AcuityMD today announced that its commercial intelligence platform for medical technology (MedTech) companies has been selected by Pristine Surgical, a medical device company with a mission to simplify endoscopy. Pristine Surgical is leveraging the platform to more efficiently and effectively roll out the world’s first single-use arthroscope: Summit™. AcuityMD’s intuitive platform is built for the unique MedTech commercial process and combines streamlined workflows with robust data, enabling sales teams to build comprehensive strategies focused on their best opportunities.

AcuityMD today announced $45 million in new funding to expand its commercial intelligence platform and advance the company’s mission of accelerating adoption of cutting-edge medical technology (MedTech). The Series B round was led by ICONIQ Growth, with additional participation from Boston-based Atreides Management and New York-based Stepstone Group as well as existing investors Redpoint Ventures, Benchmark Capital, and Artisanal Ventures. To date, AcuityMD has raised more than $83 million and achieved a significant 10x increase in annual recurring revenue since its 2022 Series A raise.

AcuityMD today announced its commercial intelligence platform for medical technology (MedTech) companies is now leveraged by more than 200 MedTech organizations, including six of the top 10 global MedTech companies, to modernize commercial operations and grow revenue. BD (Becton, Dickinson and Company) expanded use of AcuityMD’s platform to two divisions and more than 300 users, replacing manual processes with rich, real-time data analytics and insights to rapidly grow market share.

AcuityMD’s novel commercial platform for medical technology (MedTech) companies was selected by LivsMed, manufacturer of ArtiSential articulating instruments for laparoscopic surgeries. LivsMed will employ AcuityMD’s platform throughout the U.S. to accelerate commercialization of ArtiSential products, which feature a double-jointed end effector and an ergonomic grip that facilitate the surgeon’s natural movements. The devices enable surgeons to experience the same articulating advantages of expensive robotic platforms at a fraction of the price, while giving tactile feedback that robotic systems cannot provide.

AcuityMD, provider of a novel commercial platform for medical technology (MedTech) companies, announced that Intellijoint Surgical, developer of surgical planning and navigation solutions for total hip and knee joint replacements, will leverage its platform to identify new business prospects, manage pipeline, and scale operations. Intellijoint’s easy-to-use devices are used by leading orthopedic surgeons globally.

AcuityMD, provider of a novel commercial platform for medical technology (MedTech) companies, announced the launch of Pipeline, a new module that enables sales representatives to execute on prospects throughout the sales lifecycle, track progress, forecast accurately, and ultimately improve business planning to grow revenue.

AcuityMD, provider of a novel commercial platform for medical technology (MedTech) companies, has expanded its partnership with Olympus Corporation, a top 20 MedTech company that delivers advanced diagnostic, therapeutic, and minimally invasive procedures to healthcare professionals (HCPs). Olympus is leveraging AcuityMD not only to expand business opportunities but also to continue building its omnichannel strategy and improve the customer experience with personalized engagement.

AcuityMD, provider of a novel commercial platform for medical technology (MedTech) companies, celebrates signing more than 100 customers, including most recently, Miach Orthopedics. Miach manufactures bio-engineered orthopedic implants for connective tissue restoration, specifically to restore the native ACL. With AcuityMD, Miach has significantly increased its quarterly growth, and its products have treated more than 1,500 patients. Overall, AcuityMD’s platform has helped MedTech commercial teams identify more than 60,000 physicians for their innovations, equating to over $6 billion in opportunity value.

AcuityMD, providers of a novel commercial platform for medical technology (MedTech) companies, announces its partnership with FEMSelect, a MedTech manufacturer specializing in a minimally invasive approach to treat pelvic floor disorders (PFD). FEMSelect is leveraging AcuityMD’s platform to accelerate identification and engagement of U.S. physicians treating PFDs, which affect at least one in five women.

AcuityMD, providers of a novel commercial platform for medical technology (MedTech) companies, has signed a multi-year contract with Dilon Technologies, a global leader in devices for breast cancer treatment and diagnosis. Dilon is using AcuityMD’s platform to accelerate identification and engagement of physicians treating surgical breast cancer patients to help stave off re-excision surgeries, which occur a surprising average of 20% of the time after a primary lumpectomy in the U.S. In the first month alone, AcuityMD’s platform enabled Dilon to research over 1,700 new surgeons and their clinical practices to quickly determine if their patients may benefit from MarginProbe.

AcuityMD, providers of a novel commercial platform for medical technology (MedTech) companies, is ending 2022 with impressive business, customer, and employee growth. Founded in 2019, the start-up increased its annual recurring revenue (ARR) by 317%, customer growth by 253%, and new hires by 246%. For comparison, the average revenue growth rate for B2B software companies in the U.S. between two and four years of age is currently 82%.

Spark Biomedical, a leading developer of wearable neurostimulation solutions, has partnered with AcuityMD, a commercial platform for medical technology companies, to accelerate Spark Biomedical’s expansion of a new and growing market for treatment of withdrawal associated with opioid use disorder. Spark Biomedical’s FDA-approved Sparrow Therapy System is a drug-free tool that includes a patient controller and earpiece that send mild electrical impulses to the brain to help alleviate opiate withdrawal symptoms.

AcuityMD, a platform for commercializing and improving medical devices with data, announced today the close of a $7 million financing round led by Benchmark with participation from Ajax Health. Eric Vishria, General Partner at Benchmark will also join AcuityMD’s board of directors.